QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS

Pharmaceutical compositions for oral administration comprising a compound of formula (lb) or (Ic) or an enantiomer, diastereomer, tautomer, or salt thereof, and a pharmaceutically acceptable vehicle or diluent:wherein X, Y, Z, R13a - d, R13a-2-d-2and R25are described herein. The compounds are useful...

Full description

Saved in:
Bibliographic Details
Main Authors NEELS, James, LLOYD, John, BANERJEE, Abhisek, JOHNSON, James A, DHONDI, Naveen Kumar, JIANG, Ji, GUNAGA, Prashantha, ADISECHAN, Ashok Kumar, FINLAY, Heather
Format Patent
LanguageEnglish
French
German
Published 27.10.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Pharmaceutical compositions for oral administration comprising a compound of formula (lb) or (Ic) or an enantiomer, diastereomer, tautomer, or salt thereof, and a pharmaceutically acceptable vehicle or diluent:wherein X, Y, Z, R13a - d, R13a-2-d-2and R25are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
Bibliography:Application Number: EP20190186129